

Company name: MetaSight Diagnostics

Website: <https://metasightdx.com/>

CEO name: Prof. Tomer Shlomi

o Executive Summary MetaSight develops blood-based diagnostics in multiple disease areas based on low-cost assays that are applicable for wide population screening. The company is running the world's largest multi-disease study - the Israeli Multi-OMICS Screening trial (IMOSS-500K), supporting ongoing development of robust diagnostic products; for a fraction of the cost and time versus competitors.

o Core Technology MetaSight employs proprietary technology in the field of mass-spectrometry that enables low-cost and high-throughput analysis of chemical composition of blood samples with metabolomics, lipidomics, and proteomics techniques. These unique multi-OMICS capabilities are combined with access to serum samples and electronic healthcare records on a massive scale via a collaboration with a local HMO; partnering with Kahn-Sagol-Maccabi Research and Innovation.

o Product Pipeline MetaSight's pipeline consists of diagnostic products in diverse clinical domain, including oncology, GI, cardiovascular diseases, etc. Two first products have completed comprehensive validation via multiple external patient cohorts, showing a marked advantage over existing tests, and are prepared for FDA trials: (i) a test for liver fibrosis/NASH; and (ii) a colorectal cancer screening test; targeting multi \$B diagnostic opportunities.

o Business Strategy MetaSight aims to commercialize LC-MS and immunoassay based diagnostic kits to global clinical testing companies. We collaborate with major diagnostic equipment companies to implement our tests on clinical IVD equipment; and with Pharma companies on customizing the development of diagnostic products for clinical trials / companion diagnostics.

o What's Next? Moving forward, we aim to initiate clinical studies towards FDA approvals of our first two diagnostic products; and continue advancing our diagnostic pipeline based on our IMOSS-500K study.